TABLE 2.
Delivery of TAM‐specific immunotherapeutic agents in BC
| Ligands/ Receptors | Therapeutic agents | Delivery systems | Signaling pathways | Tumor cell lines | References |
|---|---|---|---|---|---|
| Fc/ Fc γ receptor | IgG3 Fc | MSN‐Fc | NF‐κB | 4T1 | 146 |
| HA/ CD44 | Methotrexate | PeiPLGA‐MTX NPs | STAT3/ NF‐κB | 4T1 | 147 |
| Galactomannan/ CD206 | HC | PSGM‐HCNP | STAT3 | 4T1 | 148 |
| RSL3 | MIL88/RSL3 | STAT1, IRF5, NF‐κB | 4T1 | 151 | |
| Imiquimod | PLGA‐ION‐R837@M | IRF5, TLR7 | 4T1 | 149 | |
| Mannose/ CD206 | HA | Man‐HA‐MnO2 | TLR4 | 4T1 | 150 |
| mUNO/ CD206 | Resiquimod | LNPs | TLR7/8 | 4T1 | 124 |
| FA/ FR | TLR7a/PI3Ki | FA‐TLR7a/FA‐PI3Ki | TLR7 or PI3K | 4T1 | 123 |
| Mannose/ CD206 | 3‐MA | PHNPs@DPA‐S‐S‐BSA‐MA@3‐MA | P13K | MDA‐MB‐231 | 152 |
| αvβ3‐mimetic antagonist/ integrin | MI3‐PD | αvβ3‐MI3‐PD NP | c‐MYC | 4T1 | 153 |
| GRP78P/ GRP78 proteins | IL‐12 | TRN | IL‐12 | 4T1 | 154 |
| Dextran/ CD206 | BLZ‐945 | DH@ECm | CSF1R | 4T1 | 156 |
| GBI‐10/Tenascin‐C | ZA | Apt@(DGL‐ZA)n NPs | NF‐κB | 4T1 | 158 |
| DNA scaffolds/ Scavenger receptor | E64 | E64‐DNA | Cysteine proteases | E0771 | 159 |
| BLZ‐945+ selumetinib | DSN | CSF1R and MAPK | 4T1 | 165 | |
| MP/ CD206 + TLR4 + TLR2 | MP + CQ | MP‐ss‐PLGA@CQ | NF‐κB and TFEB | 4T1 | 164 |
| CSF1R inhibitor +SHP2 inhibitor | DNTs | CD47 and CSF1R | 4T1 | 166 | |
| Sorafenib+aCD47 | DLG | CD47 and MAPK | 4T1 | 167 | |
| aCD47 | CALR+ aCD47 | SNPACALR&aCD47 | CD47 and CALR | 4T1 | 134 |